In the last trading session, 1.02 million Kura Oncology Inc (NASDAQ:KURA) shares changed hands as the company’s beta touched 0.78. With the company’s per share price at $7.34 changed hands at $0.05 or 0.69% during last session, the market valuation stood at $592.74M. KURA’s last price was a discount, traded about -219.89% off its 52-week high of $23.48. The share price had its 52-week low at $6.79, which suggests the last value was 7.49% up since then. When we look at Kura Oncology Inc’s average trading volume, we note the 10-day average is 1.32 million shares, with the 3-month average coming to 1.66 million.
Analysts gave the Kura Oncology Inc (KURA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.44. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended KURA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Kura Oncology Inc’s EPS for the current quarter is expected to be -0.64.
Kura Oncology Inc (NASDAQ:KURA) trade information
Instantly KURA was in green as seen at the end of in last trading. With action 0.14%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -15.73%, with the 5-day performance at 0.14% in the green. However, in the 30-day time frame, Kura Oncology Inc (NASDAQ:KURA) is -11.35% down. Looking at the short shares, we see there were 9.21 million shares sold at short interest cover period of 5.4 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12.5, meaning bulls need an upside of 41.28% from its current market value. According to analyst projections, KURA’s forecast low is 11 with 14 as the target high. To hit the forecast high, the stock’s price needs a -90.74% plunge from its current level, while the stock would need to soar -49.86% for it to hit the projected low.
Kura Oncology Inc (KURA) estimates and forecasts
Year-over-year growth is forecast to reach 148.68% up from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 39.08M. 12 analysts are of the opinion that Kura Oncology Inc’s revenue for the current quarter will be 26.82M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -6.05%. The 2025 estimates are for Kura Oncology Inc earnings to increase by 10.36%, but the outlook for the next 5-year period is at 3.45% per year.
KURA Dividends
Kura Oncology Inc is expected to release its next quarterly earnings report on 2025-Feb-25.
Kura Oncology Inc (NASDAQ:KURA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.15% of Kura Oncology Inc shares while 102.19% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 103.37%. There are 102.19% institutions holding the Kura Oncology Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 8.302% of the shares, roughly 6.97 million KURA shares worth $143.43 million.
SUVRETTA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 8.1602% or 7.07 million shares worth $145.56 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 2.75 shares estimated at $20.21 million under it, the former controlled 3.41% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.44% of the shares, roughly 1.97 shares worth around $14.46 million.
